In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner.
The MDedge cardiology team reviews three big stories from the 2019 annual scientific sessions of the American Heart Association in Philadelphia.
* * *
Help us make this podcast better! Please take this short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019
* * *
ISCHEMIA trial hailed as practice changing
The results of the ISCHEMIA trial were emphatically declared practice changing by interventional cardiologists and noninterventionalists alike at the AHA meeting.
Bruce Jancin discusses the story.
DAPA-HF: Dapagliflozin's HFrRF efficacy confirmed in nondiabetes
The results in nondiabetics from the practice-changing DAPA-HF trial gives clinicians strong evidence that the diabetes drug dapagliflozin is equally effective at reducing cardiovascular death and acute exacerbations in heart failure patients regardless of diabetes status.
Mitchel L. Zoler discusses this report.
Weakness exposed in valsartan recall
ED visits for hypertension in the month after the 2018 recall spiked 55%. The 2018 recall of generic forms of the antihypertensive drug valsartan exposed weaknesses in the recall systems for generics in both the U.S. and Canada that caused many patients who were on the drug to fall through the cracks.
Richard Mark Kirkner goes deeper into this story.
* * *
For full coverage of AHA 2019 visit MDedge Cardiology
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgeCardio
PCI reduces mortality after STEMI in older adults
Alirocumab reduces MIs
Too much hype for radial access PCI?
Ticagrelor reversal and certification changes
Top News from ACC 19
New LDL-lowering drug is under FDA review
Forget what you learned about infective endocarditis
A weight-loss drug is poised for expanded indication
Who is least adherent to statins, and more
What comes first with SGLT2 inhibitors – diabetes or heart failure?
'Simple' way to cut PAD risk, misguided ED visits for atrial fib, and more
Atrial fib guidelines updated, SPRINT MIND published, and more
FDA: Benefits still outweigh risks from paclitaxel-coated devices for PAD
Sleep: Too much, too little both tied to atherosclerosis
Biodegradable stent polymer offers no long-term protection
Reducing heart failure readmissions raises mortality
Societies refresh diabetes and PAD guidance
AHA statement on statin risks, app that diagnoses STEMI, and more
Withdrawing heart failure meds, the best DOAC for octogenarians, and more
AHA jewels, readmissions not best at 'Best Hospitals,' and more
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive